The era of targeting these proteins at an early stage to minimise risk of Alzheimer’s progressing has started. The prospect ...

Tolcapone is under clinical development by Corino Therapeutics and currently in Phase II for Familial Amyloid Cardiomyopathy.

Ke Hou generated a compound that prevents tau aggregation in the murine brain, but the potential Alzheimer’s disease therapy ...

thh.nhs.uk The amyloidoses are a group of diseases in which amyloid, a proteinaceous substance, deposits in one or more organs. As many as 23 different precursor proteins to the formation of amyloid ...

Drinking up to five cups of coffee a day may be enough to reduce your risk of cognitive decline especially in people with ...

A central symptom of AD is accumulating plaques containing β-amyloid causing synaptic failure, leading to neuronal death. Thanks to the advent of induced pluripotent stem cells (iPSCs), the ...

Cedar Valley Clinical Research in Waterloo is seeking participants for a clinical study of an investigational medication for ...

A survival analysis with a mean follow-up of 80.4 months calculated odds ratios (ORs) for incident dementia and cognitive impairment among PET-positive patients, revealing a strong link between ...

Researchers from Washington University in St. Louis found people who took suvorexant, a common treatment for insomnia, for ...

Biogen has taken up an option on a technology developed by Denali that it thinks could help improve the safety and efficacy of amyloid-targeting drugs for Alzheimer’s disease. The technology ...

The easiest way to track down "when" in a chronic disorder like AD is with the causal quartet, those carrying disease-causing mutations in APP, PSEN1, PSEN2 and SORL1, and, as you expand, including ...